New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
12:30 EDTPRGOPerrigo announces launch of betamethasone valerate foam 0.12%
Perrigo announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, , which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition. Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40M as measured by Symphony Health.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent PRGO news | >>
April 9, 2015
08:10 EDTPRGOLeerink sees 70% chance of Mylan buying Perrigo with raised bid
Subscribe for More Information
06:20 EDTPRGOTeva bid for Mylan possible, but challenging, says Citigroup
Subscribe for More Information
06:15 EDTPRGOCiti does not see much strategic sense in Mylan, Perrigo deal
Subscribe for More Information
06:02 EDTPRGOPerrigo downgraded to Market Perform from Outperform at William Blair
William Blair downgraded Perrigo (PRGO) to Market Perform after the stock rallied 18% yesterday on Mylan's (MYL) proposal to buy the company for $205 per share.
April 8, 2015
16:22 EDTPRGOOn The Fly: Closing Wrap
Subscribe for More Information
15:27 EDTPRGOMylan hasn't made compelling case for Perrigo adding value, says BMO Capital
Subscribe for More Information
15:16 EDTPRGOPerrigo not likely interested in a Mylan deal, says BMO Capital
14:23 EDTPRGOAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTPRGOMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTPRGOPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:17 EDTPRGOOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTPRGOPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTPRGOMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTPRGOPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTPRGOPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
08:56 EDTPRGOPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information
1 | 2 | 3 | all recent PRGO news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use